tiprankstipranks
Advertisement
Advertisement
Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
PremiumThe FlyArcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley
2M ago
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
Premium
Ratings
Arcutis Biotherapeutics: Buy Rating Reaffirmed as Zoryve Momentum Supports Growth Outlook; $35 Price Target Maintained
2M ago
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
Premium
Ratings
Analyst Reiterates Buy on Arcutis as Zoryve Momentum, New Data Support Unchanged $34 Price Target
2M ago
Arcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
PremiumRatingsArcutis Biotherapeutics: Near-Term Cost Pressures but Intact Long-Term Growth Thesis Supports Buy Rating
3M ago
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
Premium
The Fly
Arcutis Biotherapeutics presents new Phase 2 results on Zoryve cream
3M ago
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
Premium
The Fly
Arcutis Biotherapeutics to present clinical data on ZORYVE at AAD Meeting
4M ago
Arcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
PremiumThe FlyArcutis first participant enrolled in Phase 1a/1b trial of ARQ-234-131
4M ago
Arcutis Biotherapeutics price target lowered to $35 from $37 at Mizuho
Premium
The Fly
Arcutis Biotherapeutics price target lowered to $35 from $37 at Mizuho
4M ago
Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim
Premium
The Fly
Arcutis Biotherapeutics price target raised to $35 from $34 at Guggenheim
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100